Immune Checkpoint Inhibitor–Associated Myocarditis: A Retrospective Case Series
References
- SIEGEL RL, GIAQUINTO AN, JEMAL A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):7–33.
- POSTOW MA, SIDLOW R, HELLMANN MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
- SCHNEIDER BJ, NAIDOO J, SANTOMASSO BD, LACCHETTI C, ADKINS S, ANADKAT M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126.
- MAHMOOD SS, FRADLEY MG, COHEN JV, NOHRIA A, REYNOLDS KL, HEINZERLING LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–1764.
- PALASKAS N, LOPEZ-MATTEI J, DURAND JB, ILIESCU C, DESWAL A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.
- LIPE DN, QDAISAT A, KRISHNAMANI PP, PARIKH R, MURTHY P, PATEL M, et al. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel). 2024;14(16):1794.
- BAIK AH, OLUWOLE OO, JOHNSON DB, SHAH N, SALEM JE, TSAI KK, et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res. 2021;128(11):1780–1801.
- FERREIRA VM, SCHULZ-MENGER J, HOLMVANG G, KRAMER CM, CARBONE I, SECHTEM U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: updated Lake Louise criteria. J Am Coll Cardiol. 2018;72(24):3158–3176.
- ROSSI VA, GAWINECKA J, DIMITRIOU F, et al. Value of troponin T versus troponin I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis. ESC Heart Fail. 2023;10(4):2680–2685.
- CAFORIO ALP, PANKUWEIT S, ARBUSTINI E, BASSO C, GIMENO-BLANES J, FELIX SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis. Eur Heart J. 2013;34(33):2636–2648.
- DRAZNER MH, BOZKURT B, COOPER LT, AGGARWAL NR, BASSO C, BHAVE NM, et al. 2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis. J Am Coll Cardiol. 2024;83:In press.
- POWER JR, DOLLADILLE C, OZBAY B, PROCUREUR A, EDERHY S, PALASKAS NL, et al. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J. 2025;46:In press.
- AXELROD ML, MEIJERS WC, SCREEVER EM, QIN J, CARROLL MG, SUN X, et al. T cells specific for alpha-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7936):818–824.
- CHO J, KIM HS, KU BM, CHOI YL, CRISTESCU R, HAN J, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37(24):2162–2170.
- SHELLY S, AGMON-LEVIN N, ALTMAN A, SHOENFELD Y. Thymoma and autoimmunity. Autoimmun Rev. 2011;10(12):753–758.
- PALASKAS NL, SIDDIQUI BA, DESWAL A. Steroids in immune checkpoint inhibitor myocarditis. JACC CardioOncol. 2024;6(5):800–803.
- SALEM JE, ALLENBACH Y, VOZY A, BRECHOT N, JOHNSON DB, MOSLEHI JJ, et al. Abatacept for severe immune checkpoint inhibitor–associated myocarditis. N Engl J Med. 2019;380(24):2377–2379.
- SÁNCHEZ-CAMACHO A, FERREIRA VM, LYON AR, et al. Management of immune-related myocarditis, myositis and myasthenia gravis overlap syndrome. Front Immunol. 2025;16:1597259.
- SUZUKI S, UTSUGISAWA K, YOSHIKAWA H, NAGANE Y, SATOH T, KUWANA M, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol. 2009;66(11):1334–1338.
- GANATRA S, BARAC A, ARMENIAN S, et al. Diagnosis and management of cardiovascular adverse effects of targeted oncology therapies: Bruton's tyrosine kinase, immune checkpoint, and vascular endothelial growth factor inhibitors: 2025 ACC concise clinical guidance. J Am Coll Cardiol. 2026;87(5):654–682.
Language: English
Submitted on: Dec 2, 2025
Published on: Jun 22, 2026
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Related subjects:
© 2026 Michael Acevedo Monsanto, Artur Schneider, Razvan M. Chirila, Paulamy Ganguly, Camily Morales Lopez, Eric C. Zuberi, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.